texas oncology more breakthroughs. more victories

Share:

 
 

West Texas Clinical Trials

Texas Oncology cancer centers in West Texas participate in a wide range of clinical trials and ground-breaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the West Texas area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current trials.

Our cancer researchers in the West Texas area are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the West Texas area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the West Texas area and talk to you doctor to determine which clinical trial is right for you.

Biliary Cancer

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Andrews

Phase: III

Bladder Cancer

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Abilene

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Andrews

Phase: II

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Bladder Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Bladder Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Bladder Cancer

Location: Texas Oncology-Andrews

Phase: IV

Breast Cancer

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Andrews

Phase: III

Head and Neck Cancer

Title: Ph3 GC4419 Oral Mucositis H&N View

Description: ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419)- Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer (GTI-4419-301)

Indication: Head and Neck Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: Ph3 GC4419 Oral Mucositis H&N View

Description: ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419)- Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer (GTI-4419-301)

Indication: Head and Neck Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: Ph3 GC4419 Oral Mucositis H&N View

Description: ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419)- Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer (GTI-4419-301)

Indication: Head and Neck Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Lung Cancer

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Andrews

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-Andrews

Phase: III

Lymphomas

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Abilene

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Myelofibrosis

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Abilene

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Andrews

Phase: II

Pancreatic Cancer

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Prostate Cancer

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Andrews

Phase: III

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Abilene

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Andrews

Phase: II

Solid Tumors

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Abilene

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Andrews

Phase: II

Urothelial Cancer

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Andrews

Phase: III

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Urothelial Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Urothelial Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Urothelial Cancer

Location: Texas Oncology-Andrews

Phase: IV

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Abilene

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Andrews

Phase: II

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Andrews

Phase: III

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Urothelial Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Urothelial Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Urothelial Cancer

Location: Texas Oncology-Andrews

Phase: IV

Texas Oncology-Abilene

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Abilene

Phase: II

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Abilene

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Abilene

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Abilene

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Abilene

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Abilene

Phase: II

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Abilene

Phase: III

Texas Oncology-Andrews

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Andrews

Phase: III

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Urothelial Cancer

Location: Texas Oncology-Andrews

Phase: IV

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Andrews

Phase: III

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Andrews

Phase: II

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Bladder Cancer

Location: Texas Oncology-Andrews

Phase: IV

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Andrews

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Andrews

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-Andrews

Phase: III

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Andrews

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Andrews

Phase: III

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Andrews

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Andrews

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Andrews

Phase: II

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Andrews

Phase: III

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Urothelial Cancer

Location: Texas Oncology-Andrews

Phase: IV

Texas Oncology-El Paso Cancer Treatment Center Gateway

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: Ph3 GC4419 Oral Mucositis H&N View

Description: ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419)- Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer (GTI-4419-301)

Indication: Head and Neck Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Texas Oncology-El Paso Cancer Treatment Center Grandview

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: Ph3 GC4419 Oral Mucositis H&N View

Description: ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419)- Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer (GTI-4419-301)

Indication: Head and Neck Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: Ph3 GC4419 Oral Mucositis H&N View

Description: ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419)- Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer (GTI-4419-301)

Indication: Head and Neck Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Texas Oncology-Midland Allison Cancer Center

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Urothelial Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Bladder Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Urothelial Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Texas Oncology-Odessa West Texas Cancer Center

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Urothelial Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Bladder Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Urothelial Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Phase II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Abilene

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Andrews

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Abilene

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Abilene

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Andrews

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Abilene

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Andrews

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Abilene

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR Ph2 Pemigatinib Solids FGFR View

Description: (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Indication: Solid Tumors

Location: Texas Oncology-Andrews

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Abilene

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Andrews

Phase: II

Phase III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Andrews

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: STAR Infigratinib vs Gem/Cis Cholangio View

Description: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

Indication: Biliary Cancer

Location: Texas Oncology-Andrews

Phase: III

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: Ph 3 Tuca/Placbo + T-DM1 HER2+ View

Description: STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (SGNTUC-016)

Indication: Breast Cancer

Location: Texas Oncology-Andrews

Phase: III

Title: Ph3 GC4419 Oral Mucositis H&N View

Description: ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419)- Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer (GTI-4419-301)

Indication: Head and Neck Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: Ph3 GC4419 Oral Mucositis H&N View

Description: ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419)- Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer (GTI-4419-301)

Indication: Head and Neck Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: Ph3 GC4419 Oral Mucositis H&N View

Description: ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419)- Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer (GTI-4419-301)

Indication: Head and Neck Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Andrews

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: STAR Ph3 Peme+PltChem+/-Pemb NSCLC TKI View

Description: A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)

Indication: Lung Cancer

Location: Texas Oncology-Andrews

Phase: III

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Andrews

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Abilene

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Gateway

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Joe Battle

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-El Paso Cancer Treatment Center Grandview

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: III

Title: STAR Ph3 FGFR erdafitinib urothelial View

Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)

Indication: Urothelial Cancer

Location: Texas Oncology-Andrews

Phase: III

Phase IV

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Urothelial Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Urothelial Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Urothelial Cancer

Location: Texas Oncology-Andrews

Phase: IV

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Bladder Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Bladder Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Bladder Cancer

Location: Texas Oncology-Andrews

Phase: IV

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Urothelial Cancer

Location: Texas Oncology-Midland Allison Cancer Center

Phase: IV

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Urothelial Cancer

Location: Texas Oncology-Odessa West Texas Cancer Center

Phase: IV

Title: Biomarker Advcd Uro Cncer and FGFR Aber View

Description: Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)

Indication: Urothelial Cancer

Location: Texas Oncology-Andrews

Phase: IV